Amphivena Therapeutics
PrivateLast Round
Series C
Sep 24, 2019
Total Funding Raised
$95.5M
Company Overview
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops bivalent T-cell engagers for the treatment of hematologic and solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amphivena Therapeutics Comparables
Compare Amphivena Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AvenCell | 86% | |
| Molecular Partners AG | 78% | |
| Johnson & Johnson | 77% |
Amphivena Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 24, 2019 | ||||
| Series B | Jun 26, 2017 | ||||
| Series A | Jul 1, 2013 |
Amphivena Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | Series C, Series A |
| Korys | Series C |
| Kaitai Capital | Series C |
| Aeris Capital Management | Series A, Series B |
| +ND Capital | Series C |
| MPM BioImpact | Series C, Series A, Series B |
| OrbiMed | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 24, 2019
$62M round led by +ND Capital.
- Jul 1, 2013
$14M round led by MPM BioImpact and MPM Capital.
Amphivena Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Amphivena Therapeutics's valuation, stock price, and market status.
Is Amphivena Therapeutics a public or private company?
Amphivena Therapeutics is a private company.
What is the current stock price of Amphivena Therapeutics?
Amphivena Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Amphivena Therapeutics worth (valuation)?
Valuation information for Amphivena Therapeutics is not publicly available.
Can I buy Amphivena Therapeutics stock?
Amphivena Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Amphivena Therapeutics's last funding round?
Amphivena Therapeutics's most recent funding round was Series C on September 24, 2019.
Who are the main investors in Amphivena Therapeutics?
Key investors in Amphivena Therapeutics include MPM Capital, +ND Capital.
Will Amphivena Therapeutics IPO soon?
No public IPO plans have been announced for Amphivena Therapeutics.
How can I track Amphivena Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Amphivena Therapeutics's secondary market activity and sign up for updates.